The News Review:
- Lab Documents Development Of Cancer Stem Cells
- Nutrition 21’s Selenomax(R) Suppresses Progression of the Human …
- Restarting Tumor-Suppressor Gene May Fight Cancer
- Iraq the Medical Model
- Scientists Discover New Gene Associated with Crohn’s Disease.
Lab Documents Development Of Cancer Stem Cells
Science Daily - Science Daily (press release) - Jan 24, 2007
The theory that cancer stem cells initiate and drive cancer cell growth has been gaining popularity in both clinical and basic research. Recent studies have identified cancer stem cells and shown that they may cause tumors when transplanted into a secondary host. Until now, however, little was known about the process by which mutations in a stem cell result in primary tumor initiation. The Li Lab team studied the intestinal system in mice in which one of the human tumor suppressor genes, PTEN, had been deleted… of Biochemistry, Purdue University; Leroy Hood, Institute for Systems Biology; Hong Wu, Department of Molecular and Medical Pharmacology, UCLA School of Medicine. Linheng Li also holds an appointment as Associate Professor in the Department of Pathology at the University of Kansas School of Medicine. Adapted from materials provided by.
Nutrition 21’s Selenomax(R) Suppresses Progression of the Human …
Hispanic PR Wire - Hispanic PR Wire (press release) - Jan 24, 2007
It stimulates and protects the immune system by supporting antibody production and preventing free-radical damage. Selenomax is highly absorbed and bioavailable. It contains L-selenomethionine, the natural form of selenium used by the body, which is virtually 100% absorbed and well retained. The yeast-bound L-selenomethionine which is organic, has been certified for maximum purity. More information is available at.
Restarting Tumor-Suppressor Gene May Fight Cancer
Forbes - Jan 24, 2007
"The study also uncovered surprising new insights into the powerof the human immune system to "mop up" cancers weakenedby reactivated p53. Lowe's work and a related study were published online in theJan. 25 issue of Nature. "These studies indicate that this might be a fruitful pathto explore from a cancer drug-development standpoint," saidDr. Ronald DePinho, a pioneer in this type of work and a professorof medicine at Harvard Medical School. Although an actual drug for use in a clinical setting is still along way off, "there are compounds that are now being directedtoward the p53 kinase pathway that may enable re-establishment ofp53 activity," said DePinho, who also authored a relatedcommentary on the studies. Almost all forms of cancer involve an inactivation of the p53tumor-suppressor gene and its related biochemical pathway… 25 issue of Nature. "These studies indicate that this might be a fruitful pathto explore from a cancer drug-development standpoint," saidDr. Ronald DePinho, a pioneer in this type of work and a professorof medicine at Harvard Medical School. Although an actual drug for use in a clinical setting is still along way off, "there are compounds that are now being directedtoward the p53 kinase pathway that may enable re-establishment ofp53 activity," said DePinho, who also authored a relatedcommentary on the studies. Almost all forms of cancer involve an inactivation of the p53tumor-suppressor gene and its related biochemical pathway. So, thepathway has long been a favorite target of cancer research. "What p53 does is help cells solve problems when they arestressed," Lowe explained.
Iraq the Medical Model
Conservative Voice - The Conservative Voice - Jan 24, 2007
That had never happened before! And even more astounding, he survived to walk out of the hospital and go back to serving as a crossing guard. He performed this duty several more years, in fact. Medical illnesses frequently have this empirical nature. That is, you don’t know how the illness will play out and whether the patient will respond to a specific treatment or not until it’s been given a fair trial. The situation is analogous to the war on terror in general and the war in Iraq more specifically. There is no way to know how it will be resolved until the specific “medicine” has been given a fair trial. One surely doesn’t know the likelihood of success if one isn’t going to begin the “treatment” at all… That is, you don’t know how the illness will play out and whether the patient will respond to a specific treatment or not until it’s been given a fair trial. The situation is analogous to the war on terror in general and the war in Iraq more specifically. There is no way to know how it will be resolved until the specific “medicine” has been given a fair trial. One surely doesn’t know the likelihood of success if one isn’t going to begin the “treatment” at all. If the commander-in-chief has tried an approach and it hasn’t worked, just as if a physician has tried an antibiotic and it hasn’t worked, it makes sense to try another, not to give up!The “law enforcement” model of treating terrorism had certainly been given a fair try, as various presidents and the United Nations had tried negotiations, legal proceedings, trials, and other “police” models on the terrorists for many years. Specifically, the Clinton administration had pursued this legal model.
Scientists Discover New Gene Associated with Crohn’s Disease.
Free with registration - Business Wire - AccessMyLibrary.com - Jan 24, 2007
& KIEL, Germany — Scientists have discovered another piece of the genetic puzzle that may predispose humans to Crohn’s disease, a complex disorder characterized by chronic inflammation of the digestive tract. The findings may also suggest new strategies for treating this chronic, debilitating disease. Researchers from the University Hospital of the Christian-Albrechts University in Kiel, Germany and Applied Biosystems (NYSE: ABI), an Applera Corporation Business, have identified and characterized a novel genetic variation in a gene not previously associated with the disorder that provides further evidence that an abnormal immune response to bacteria in the digestive tract may lead to the intestinal inflammation characteristic of the.
Leave a Comment